
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience is making significant progress in their clinical-stage assets for treatingeffective treatments for depressive disorders and schizophrenia by leveraging individual neurobiology-based biomarkers.Alto's recent financing extends their cash runway through 2030 to support planned operations and timelines for their clinical trials. With a three-trial program in place, as well as a new monotherapy Phase 3 trial, the company is well-positioned to potentially accelerate their path to a new drug application (NDA) and increase interest in their drugs. Additionally, positive data from the PRIME-PRAXOL trial and the expected readouts from their lead programs could further validate their precision psychiatry model and drive potential upside for the stock.
Bears say
Alto Neuroscience is a clinical-stage biopharmaceutical company with a strong development program but limited financial stability. With cash runway now through 2030, the company's main risks lie in the highly competitive and price-sensitive market for its product candidates. Without significant market traction, the company may struggle to maintain its current valuation and presents a risky investment opportunity for the financial analyst.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares